Adverse events/serious adverse events · people with NMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events/serious adverse events · people with NMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events within 28 days · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
1 finding from 1 review
Adverse events: Cushingoid appearance · children with nephrotic syndrome
Steroid therapy in first episode of nephrotic syndrome: five to… showed no clear difference in adverse events: Cushingoid appearance compared with three months (moderate certainty).
1 finding from 1 review
Adverse events: yellowing of the skin · healthy people and healthy male physicians
Vitamin A leads to higher adverse events: yellowing of the skin compared with placebo (high certainty).
1 finding from 1 review
Proportion of children adverse events · children with nocturnal enuresis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of mothers with serious adverse events ( · opiate‐dependent pregnant women
Methadone showed no clear difference in serious adverse events for the mother compared with buprenorphine (low certainty).
1 finding from 1 review
Adverse events (maternal or neonatal) · women undergoing caesarean section
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (maternal or neonatal) · women undergoing caesarean section
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (timing not specified) · people undergoing major amputation of the lower extremity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events – relapse 12–60 months · adults with a chronic or recurrent condition
Patient‐initiated appointment systems showed no clear difference in adverse events – relapse 12–60 months compared with consultant‐led appointment systems (low certainty).
1 finding from 1 review
Adverse events: myocardial infarction · cognitively healthy people in late life
Other NSAIDs showed no clear difference in adverse events –myocardial infarction compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events ‐ not reported · participants with quiescent IBD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ‐ not reported · participants with quiescent IBD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Tivozanib may leads to lower serious adverse events (Grade 3 or 4) compared with sorafenib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
It is very uncertain whether sorafenib changes serious adverse events (Grade 3 or 4) compared with pazopanib (targeted agent versus targeted agent) (very low certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Sunitinib probably leads to higher serious adverse events (Grade 3 or 4) compared with everolimus (targeted agent versus targeted agent) (moderate certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Sunitinib showed no clear difference in serious adverse events (Grade 3 or 4) compared with avelumab + axitinib (targeted agent versus immunotherapy + targeted… (low certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Sunitinib showed no clear difference in serious adverse events (Grade 3 or 4) compared with pembrolizumab + axitinib (targeted agent versus immunotherapy +… (low certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
It is very uncertain whether sorafenib changes serious adverse events (Grade 3 or 4) compared with sunitinib (targeted agent versus targeted agent) (very low certainty).
1 finding from 1 review